40 results on '"Wu Z"'
Search Results
2. 773P Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer
3. LBA22 Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial
4. 1424P Landscape of germline mutations in Chinese patients with gastric cancer
5. 1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)
6. LBA26 Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial
7. 1364P ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
8. 1332P Efficacy and safety of gefitinib plus bevacizumab versus gefitinib monotherapy in patients with EGFR L858R mutant non-small cell lung cancer (NSCLC): A randomized, open-controlled, single-center trial
9. 1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers
10. 642P A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
11. 499O A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated
12. 506MO A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma
13. 387P Detection of 1p/19q deletion in gliomas with high accuracy by combining sequencing depth and heterozygous SNV allele frequency
14. 2O Growth differentiation factor 15 (GDF-15) neutralization reverses cancer cachexia, restores physical performance and mitigates emesis associated with platinum-based chemotherapy
15. 169MO Development and validation of a magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with breast cancer: A multicenter cohort study
16. 1018TiP ALTER-H-004: A phase II study of anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post-surgery recurrence
17. A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib)
18. 491P Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience.
19. 218P Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study.
20. Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer
21. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
22. Prediction of and intervention in colorectal cancer risk with artificial intelligent system
23. The frequency of RAS mutation in circulating tumor DNA predicts worse survival in patients with mCRC
24. CLASS-05 trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer
25. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
26. 1377TiP - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib)
27. 191P Safety and preliminary efficacy of modified FOLFOXIRI in advanced colorectal cancer: Single institution experience
28. 181P Initial CEA and CA19-9 level were associated with pathologic outcome of locally advanced rectal cancer after neoadjuvant chemotherapy with or without radiotherapy: Results from a prospective study
29. Reduction of blood total lymphocyte count after neoadjuvant treatment is correlated with good tumor regression—results from a prospective randomized control trial
30. 87O - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
31. 497P - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
32. 12P - Prediction of and intervention in colorectal cancer risk with artificial intelligent system
33. 27PD Plasma miRNA-based signatures to predict 3-year postoperative recurrence risk for patients with stage II and III gastric cancer
34. 544P - The frequency of RAS mutation in circulating tumor DNA predicts worse survival in patients with mCRC
35. 767TiP - CLASS-05 trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer
36. 389P - Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
37. 591P - Reduction of blood total lymphocyte count after neoadjuvant treatment is correlated with good tumor regression—results from a prospective randomized control trial
38. Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non-Small Cell Lung Cancer
39. P-019 - Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer.
40. 392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.